The effect of federal and state off-label marketing investigations on drug prescribing: The case of olanzapine.
In the past decade, the federal government has frequently investigated and prosecuted pharmaceutical manufacturers for illegal promotion of drugs for indications not approved by the Food and Drug Administration (FDA) ("off-label" uses). State governments can choose to coordinate with the f...
Main Authors: | Bo Wang, David M Studdert, Ameet Sarpatwari, Jessica M Franklin, Joan Landon, Aaron S Kesselheim |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5384770?pdf=render |
Similar Items
-
Paying physicians to prescribe generic drugs and follow-on biologics in the United States.
by: Ameet Sarpatwari, et al.
Published: (2015-03-01) -
Strategies and practices in off-label marketing of pharmaceuticals: a retrospective analysis of whistleblower complaints.
by: Aaron S Kesselheim, et al.
Published: (2011-04-01) -
Conflict of interest reporting by authors involved in promotion of off-label drug use: an analysis of journal disclosures.
by: Aaron S Kesselheim, et al.
Published: (2012-01-01) -
Did FDA Decisionmaking Affect Anti-Psychotic Drug Prescribing in Children?: A Time-Trend Analysis.
by: Bo Wang, et al.
Published: (2016-01-01) -
The next forum for unraveling FDA off-label marketing rules: State and federal legislatures.
by: Michael S Sinha, et al.
Published: (2018-05-01)